Table 2 List of patient’s background factors and comparison of the two groups
Hydromorphone hydrochloride group (n = 27) | Morphine hydrochloride group (n = 32) | P | |
|---|---|---|---|
Age (< 75/≥75) | 24/3 | 28/4 | 0.75*) |
Sex (Male/ Female) | 10/17 | 19/13 | 0.12*) |
Performance status (≤ 3/4) | 5/22 | 4/28 | 0.72*) |
Body mass index (< 25/≥25) | 23/4 | 26/6 | 0.74*) |
Concomitant steroid use (Yes/No) | 15/12 | 24/8 | 0.17*) |
Concomitant non-opioid analgesics use (Yes/No) | 9/18 | 17/15 | 0.19*) |
Concomitant anti-histamine use (Yes/No) | 7/20 | 4/28 | 0.31*) |
Dilution with saline solution (Yes/No) | 4/23 | 2/30 | 0.40*) |
Starting flow rate (< 0.5 mL/h/≥0.5 mL/h) | 25/2 | 32/0 | 0.20*) |
Daily dosage (morphine equivalent < 60 mg/day/≥60 mg/day) | 3/24 | 6/26 | 0.49*) |
Administration period (< 28 days/≥28 days) | 20/7 | 26/6 | 0.54*) |